Kun-Ho Yoon
Quick facts
Marketed products
- alogliptin + pioglitazone · Diabetes
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels, while pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: